IP Library Granted Patent US 10,912,610
Granted Patent B2
US 10,912,610 · App. 16/510,503 · Granted Feb 9, 2021

Devices and methods for treatment of heart failure by splanchnic nerve ablation

Inventors: Howard Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: Axon Therapies, Inc.
A61B18/1492A61N1/00A61N1/36017A61B2018/00214A61B2018/00404A61B2018/00434A61B2018/00791A61B2018/00863A61B2018/00875A61B2090/064
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,912,610
App. No.
16/510,503
Granted
Feb 9, 2021
Kind
B2
Abstract

A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.

Claims (35)

1. A method for increasing splanchnic venous compliance in a patient, comprising:

positioning an endovascular catheter comprising a proximal region, a flexible shaft, and a distal region, wherein the flexible shaft connects the proximal and distal regions and is a length sufficient to access a T9, T10, or T11 intercostal vein of the patient relative to an access location when the proximal region remains external to the patient, the distal region comprising at least one ablation element;

advancing the distal region through an azygous vein;

advancing the distal region from the azygous vein and into the T9, T10, or T11 intercostal vein;

activating the at least one ablation element;

ablating a greater splanchnic nerve using energy generated with the at least one ablation element; and

removing the endovascular catheter from the patient.

2. The method of claim 1 , further comprising confirming a proper position of the at least one ablation element in the T9, T10 or T11 intercostal vein.

3. The method of claim 1 , further comprising confirming that the greater splanchnic nerve has been ablated.

4. The method of claim 1 , wherein the at least one ablation element comprises a balloon, the method further comprising expanding the balloon in the T9, T10, or T11 intercostal vein prior to the ablating with the at least one ablation element.

5. The method of claim 4 , wherein the balloon has a cylindrically shaped expanded configuration, wherein expanding the balloon comprises expanding the balloon towards the cylindrically shaped configuration.

6. The method of claim 4 , wherein expanding the balloon comprises expanding the balloon to have a diameter from 2 mm-6 mm.

7. The method of claim 4 , wherein expanding the balloon comprises distending a wall of the T9, T10, or T11 intercostal vein.

8. The method of claim 1 , wherein advancing the distal region from the azygous vein and into the T9, 1710, Of T11 intercostal vein comprises advancing the distal region into a right T9, T10 or T11 intercostal vein.

9. A method for increasing splanchnic venous compliance in a patient, comprising:

positioning at least one ablation element in a T9, T10, or T11 intercostal vein of the patient;

activating the at least one ablation element;

ablating a greater splanchnic nerve using energy generated with the at least one ablation element; and

removing the at least one ablation element from the patient.

10. A method for treating a patient diagnosed with heart failure, comprising:

positioning at least one ablation element in a T9, T10, or T11 intercostal vein of the patient;

activating an enemy source;

ablating a greater splanchnic nerve using energy delivered with the at least one ablation element; and

removing the at least one ablation element from the patient.

11. The method of claim 10 , wherein the method is a method for treating a patient diagnosed with heart failure with preserved ejection fraction.

12. The method of claim 10 , further comprising, at a time subsequent to activating the energy source, assessing the patient's heart failure by assessing one or more of the patient's exercise capacity, blood pressure, or neurohormonal changes.

13. The method of claim 10 , further comprising confirming a proper position of the at least one ablation element in the T9, T10 or T11 intercostal vein.

14. The method of claim 10 , further comprising confirming that the greater splanchnic nerve has been ablated.

15. The method of claim 10 , further comprising expanding an inflatable balloon in the T9, T10, or T11 intercostal vein prior to the ablating step.

16. The method of claim 15 , wherein the inflatable balloon is adapted to have a cylindrically shaped expanded configuration, wherein expanding the inflatable balloon comprises expanding the inflatable balloon towards the cylindrically shaped configuration.

17. The method of claim 16 , wherein expanding the inflatable balloon comprises expanding the inflatable balloon to have a diameter from 2 mm-6 mm.

18. The method of claim 10 , further comprising advancing the at least one ablation element in an azygous vein.

19. The method of claim 10 , wherein positioning the at least one ablation element in the T9, T10, or T11 intercostal vein of the patient comprises positioning the at least one ablation element into a right T9, T10, or T11 intercostal vein.

20. The method of claim 10 , wherein ablating the greater splanchnic nerve using the energy delivered with the at least one ablation element treats heart failure and causes an increase in exercise tolerance.

21. The method of claim 10 , wherein ablating the greater splanchnic nerve using the energy delivered with the at least one ablation element treats heart failure and causes a decrease in blood pressure.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2025
From: AXON THERAPIES, INC.
To: AXON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 071149/0588 →
PATENT ASSIGNMENT AGREEMENT Recorded Nov 13, 2024
From: AXON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: AXON VASCULAR, INC.
Reel/Frame 069353/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2019
From: LEVIN, HOWARD; GELFAND, MARK
To: AXON THERAPIES, INC.
Reel/Frame 050277/0490 →
Continuity (4)
Continuation 15017351 · Feb 5, 2018
Provisional Application 62112395 · Feb 5, 2015
Provisional Application 62162266 · May 15, 2015
Related Publication 20190350650A1 · Nov 21, 2019
Cited By (3)
US 12,349,966 US 12,661,177 US 12,708,433